Troubled Biotechs Roundup: Avigen, Jazz, Alfacell, Panacos
This article was originally published in The Pink Sheet Daily
Executive Summary
Unlike other troubled biotechs, Avigen is not cash-poor; however, it is not advancing its small pipeline and its largest investor has called foul.